Age at Which HIV Infection Can Be Detected in Infants
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 42 (3) , 362-367
- https://doi.org/10.1097/01.qai.0000220166.56866.22
Abstract
Summary: The Yakovlev parametric cure rate model was used to study the age at which HIV-1 infection can be detected in nonbreast-fed infants and the independent predictors of transmission. Blood samples from 145 HIV-1-negative at birth infants born to HIV-1-positive untreated mothers were tested until 15 months. The age at actual detection and at potential detection providing daily tests was studied. The former was described using the Yakovlev model, and the cumulative probabilities of detection along time were calculated. Comparison of observed and predicted delays to positivity revealed the best representation of the age at which HIV becomes detectable among 8 Yakovlev models. Cumulative positive tests were as follows: 3 at 7 days, 10 at 15 days and 1 month, 17 at 3 months, and 18 at 15 months. The log-logistic model was the best-fitting one. The probability of onset of HIV-1 detectability was maximal at day 4. The mean and median age at which HIV becomes detectable were 12 and 6 days, respectively. Maternal CD4+ cell count was associated with the risk of contamination [hazard ratio of low vs. high count 2.44; 95% (confidence interval): 1.15-6.67]. The model may explain HIV viremia dynamics and define the optimal antiretroviral regimens before randomized trial confirmation.Keywords
This publication has 20 references indexed in Scilit:
- Interval‐censored survival time data: confidence intervals for the non‐parametric survivor functionStatistics in Medicine, 2004
- Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV TransmissionA Randomized TrialJAMA, 2002
- Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2002
- A Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Defining the Time of Fetal or Perinatal Acquisition of Human Immunodeficiency Virus Type 1 Infection on the Basis of Age at First Positive CultureThe Journal of Infectious Diseases, 1997
- Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to InfantNew England Journal of Medicine, 1996
- Estimating the HIV Vertical Transmission Rate and the Pediatric AIDS Incubation Period from Prospective DataJournal of the American Statistical Association, 1996
- The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmissionAIDS, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- In the Vertical Transmission of HIV, Timing May Be EverythingNew England Journal of Medicine, 1991